Our technically qualified team of patent and trade mark attorneys has extensive experience in assisting chemical and healthcare companies in all aspects of their IP portfolios in marketplaces across the Asia-Pacific. Our ability to deliver high quality IP services to the chemical and healthcare sectors is enhanced by our Chemical / Life Sciences patent team comprised of scientists trained in a broad range of relevant technologies including cardiovascular, immunoscience, metabolics, neuroscience, oncology and virology. Their expertise includes patent term extensions, data exclusivity, regulatory approval and all other aspects of advice relating to our client’s core commercial products.
Our trade marks team has a long history of representing chemical and healthcare companies in trade mark matters. Our professionals have a deep understanding of the potential issues of trade mark registration of chemical and healthcare brands across the Asia-Pacific. Our dedicated trade mark searching team has experience in pharmaceutical trade mark searches and regularly conduct direct searches of relevant name and image databases.
Spruson & Ferguson Lawyers regularly advises on a wide variety of matters, from general advertising and promotion regulation to consumer protection law, as well as advice on specific biopharma industry codes of conduct and applicable biopharma legislation. Our patent litigation team has an outstanding reputation in the enforcement of IP rights and has acted in some of the most keenly contested patent cases in Australia.
Kristian Robinson is the Managing Director of Spruson & Ferguson (Asia) and Director of the firm’s Asia-Pacific patent practices. Kristian is based in the Singapore head office of our…
Kristian Robinson is the Managing Director of Spruson & Ferguson (Asia) and Director of the firm’s Asia-Pacific patent practices….
Oliver Lutze is Spruson & Ferguson’s Country Manager for China. He is based in Beijing and advises on patent matters with a special focus on China activities.
Oliver’s practice primarily…
Oliver Lutze is Spruson & Ferguson’s Country Manager for China. He is based in Beijing and advises on patent…
Simon is an experienced patent attorney specialising in biotechnology. As head of Spruson & Ferguson’s Chemical/Life Sciences team in Australia, he assists clients in all aspects of patent practice…
Simon is an experienced patent attorney specialising in biotechnology. As head of Spruson & Ferguson’s Chemical/Life Sciences team in…
The Australian enablement requirement was introduced with the IP Laws Amendment (Raising the Bar) Act 2012 that came into effect on 15 April 2013. However, some seven years later…
The Australian enablement requirement was introduced with the IP Laws Amendment (Raising the Bar) Act 2012 that came into…
Two patent applications naming artificial intelligence as the sole inventor were refused by the European Patent Office following oral proceedings on the grounds that an inventor must be a…
Two patent applications naming artificial intelligence as the sole inventor were refused by the European Patent Office following oral…
Commonwealth of Australia v Sanofi (formerly Sanofi-Aventis) (No 5) FCA 543
As reported in our article of July 2017, the Commonwealth has been seeking to establish its entitlement…
Commonwealth of Australia v Sanofi (formerly Sanofi-Aventis) (No 5) FCA 543
As reported in our article of July…
COVID-19 (short for coronavirus disease 2019) is caused by Severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), more commonly referred to as
coronavirus. Coronavirus has dominated world headlines in 2020, leading to
nationwide…
COVID-19 (short for coronavirus disease 2019) is caused by Severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), more commonly referred to…
